Posted on 6/13/18
Bristol-Myers Top NASH Contenders
There were whispers in the marketplace that Bristol Myers-Squibb (BMY) was still looking to beef up their pipeline in NASH, but Dealreporter broke the news that . . .
Posted on 3/8/18
Merck & Co. Needs A Pipeline Boost As It Eyes Future Acquisitions
Merck & Co. (MRK) has been making many strides in Immuno-Oncology (I-O) by continually expanding the indications for its blockbuster drug KEYTRUDA but investors want to . . .
New York
